POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes

Damian G. Downey*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish
Pages (from-to)18-20
Number of pages3
Issue number1
Publication statusPublished - 01 Jan 2022

Bibliographical note

Funding Information:
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. G. D. has received honoraria and acted as a clinical trial principal investigator for Vertex Pharmaceuticals and Proteostasis Therapeutics.


  • Administration, Inhalation
  • Adolescent
  • Adult
  • Age Distribution
  • Age Factors
  • Anti-Bacterial Agents/therapeutic use
  • Child
  • Child, Preschool
  • Chloride Channel Agonists/therapeutic use
  • Cystic Fibrosis/drug therapy
  • Diabetes Mellitus/drug therapy
  • Disease Management
  • Disease Progression
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Middle Aged
  • Patient Care Planning
  • Phenotype
  • Pseudomonas Infections/drug therapy
  • Young Adult

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this